Finnish Healthtech Gosta Labs Raises €7.5M for AI Operating System Targeting Oncology Workflows

Helsinki-based Gosta Labs closed an oversubscribed €7.5 million seed round to scale its artificial intelligence operating system designed for complex medical specialties, with initial focus on oncology workflows where administrative burden consumes several hours daily from clinicians.

Voima Ventures led the round, joined by COR Group, Finnish healthcare provider Terveystalo, the Aho family, existing investor Reaktor, and multiple angel investors. The funding follows a €1.7 million pre-seed round in 2024, bringing total capital raised to nearly €10 million since the company's 2023 founding.

Global cancer diagnoses are projected to exceed 35 million annual cases by 2050 across more than 100 different cancer types, according to International Agency for Research on Cancer data. Simultaneously, oncology teams operate within fragmented systems handling unstructured clinical data while making high-stakes decisions about expanding personalized treatment options.

Gosta Labs' AI operating system addresses these challenges by automating clinical documentation, structuring patient data in real-time, visualizing patient journeys, and linking care decisions to international treatment guidelines. The platform converts information from patient visits into standardized documentation notes while automatically classifying clinical parameters.

Real-world results presented at the ESMO 2025 Congress, a leading global oncology conference, demonstrated that oncologists completed follow-up visit documentation in under two minutes using the Gosta system—a reduction in administrative time exceeding two-thirds per patient visit. The system generates high-quality consultation notes structured according to institutional standards and automatically classifies Performance Status and CTCAE toxicity grades.

Founders Lauri Sippola and Henri Viertolahti bring demonstrated success in healthcare technology commercialization. The pair previously founded Kaiku Health, which Swedish radiation therapy company Elekta acquired in 2020. Their track record developing and scaling regulated digital health solutions globally provided investor confidence in executing complex healthcare AI implementations.

The executive team combines AI specialists with oncology and medical technology leaders. Chief Medical Officer Dr. Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski both possess extensive international experience scaling cancer care technologies. The leadership team maintains 40 percent female representation across four European nationalities.

"Gosta Labs' key team members combine proven startup execution, deep domain expertise and top notch AI capabilities," said Jussi Sainiemi, partner at Voima Ventures. "They've done it before and know what good looks like, which is essential for any startup team. There's a lot of hype around AI but Gosta delivers the value it promises and customers love the product."

The platform operates daily with leading healthcare providers across Finland, Switzerland, the Baltics, and Australia. The geographic diversity demonstrates the system's adaptability to different healthcare regulatory environments and clinical workflows.

CEO Lauri Sippola outlined the funding's strategic purpose: "This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration."

The company plans to accelerate product development toward full medical device certification, expand international partnerships with cancer centers, and strengthen AI model capabilities. Initial focus remains on oncology, where digital relief needs are particularly acute given the specialty's documentation complexity and decision-making stakes.

The €7.5 million round represents one of the larger early-stage financings in oncology-focused AI for 2025. Comparable announcements include London-based Perci Health's €4 million for AI-driven virtual cancer clinics, Barcelona's Sycai Medical's €3 million for early detection devices, and Leiden's BIMINI Biotech's €3 million for hematological cancer therapeutics—totaling roughly €11.7 million in similar-stage oncology AI funding.

Finland's regulatory environment provides strategic advantages. The nation's Act on the Secondary Use of Health and Social Data enables streamlined access to anonymized patient datasets, allowing Gosta Labs to train systems on longitudinal disease progression data rather than isolated snapshots—creating potential competitive moats against international rivals operating in more restrictive data environments.

As healthcare systems worldwide confront mounting administrative burden amid surging cancer case volumes, Gosta Labs' success in reducing documentation time while maintaining clinical quality positions AI operating systems as infrastructure investments rather than productivity tools—potentially reshaping how healthcare organizations approach digital transformation budgets and clinical workflow design.